Abstract
The ability to silence specific genes of choice consistently and efficiently has always been a major goal for scientists. The emerging field of RNA interference (RNAi), a process in which target mRNAs are degraded by small interfering RNA (siRNA), may indeed provide this long sought after tool. The importance of this technology has been highlighted recently by Science, which has voted the RNAi discoveries as the “ & ;Breakthrough of the Year” in 2002. Essentially, RNAi involves an initiation and an effector step whereby introduced dsRNA is digested into 19-21 duplex siRNA by cleavage with Dicer and siRNA binds to an RNA-induced silencing complex (RISC). Activation of RISC targets the homologous sequence (transcript) and results in the cleavage of mRNA. The models of this RNAi mechanism and its applications, derived from biochemical and genetic approaches, are described in this minireview. So far, RNAi has proven to be a useful technique for genomic studies in C.elegans, D.melanogaster and various plants, for example. The use of RNAi has also been invaluable in studies in which morphological and developmental variability between species was investigated. Targeted, sequence specific siRNAs that suppress or silence gene expression have the potential to be in great demand as tools for for the treatment of human disease. There have already been several studies that have utilized siRNA to inhibit HIV-1 infection and replication, for example. The expansion of RNAi for biomedical therapeutics seems inevitable. This minireview analytically summarizes the advantages and the current and future potential of RNAi technology whilst simultaneously investigating any shortfalls or difficulties. Importantly, in vitro and in vivo applications in the laboratory and in human disease models are also described.
Keywords: sirna, rnai, co-suppression, ptgs
Current Genomics
Title: Silence of the Genes: A Targeted Approach to the Suppression of Specific Genes in Human Disease Using Small Interfering RNA (siRNA)
Volume: 4 Issue: 7
Author(s): Jim Apostolopoulos
Affiliation:
Keywords: sirna, rnai, co-suppression, ptgs
Abstract: The ability to silence specific genes of choice consistently and efficiently has always been a major goal for scientists. The emerging field of RNA interference (RNAi), a process in which target mRNAs are degraded by small interfering RNA (siRNA), may indeed provide this long sought after tool. The importance of this technology has been highlighted recently by Science, which has voted the RNAi discoveries as the “ & ;Breakthrough of the Year” in 2002. Essentially, RNAi involves an initiation and an effector step whereby introduced dsRNA is digested into 19-21 duplex siRNA by cleavage with Dicer and siRNA binds to an RNA-induced silencing complex (RISC). Activation of RISC targets the homologous sequence (transcript) and results in the cleavage of mRNA. The models of this RNAi mechanism and its applications, derived from biochemical and genetic approaches, are described in this minireview. So far, RNAi has proven to be a useful technique for genomic studies in C.elegans, D.melanogaster and various plants, for example. The use of RNAi has also been invaluable in studies in which morphological and developmental variability between species was investigated. Targeted, sequence specific siRNAs that suppress or silence gene expression have the potential to be in great demand as tools for for the treatment of human disease. There have already been several studies that have utilized siRNA to inhibit HIV-1 infection and replication, for example. The expansion of RNAi for biomedical therapeutics seems inevitable. This minireview analytically summarizes the advantages and the current and future potential of RNAi technology whilst simultaneously investigating any shortfalls or difficulties. Importantly, in vitro and in vivo applications in the laboratory and in human disease models are also described.
Export Options
About this article
Cite this article as:
Apostolopoulos Jim, Silence of the Genes: A Targeted Approach to the Suppression of Specific Genes in Human Disease Using Small Interfering RNA (siRNA), Current Genomics 2003; 4 (7) . https://dx.doi.org/10.2174/1389202033490178
DOI https://dx.doi.org/10.2174/1389202033490178 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
New insights on Pediatric Tumors and Associated Cancer Predisposition Syndromes
Because of the broad spectrum of children cancer susceptibility, the diagnosis of cancer risk syndromes in children is rarely used in direct cancer treatment. The field of pediatric cancer genetics and genomics will only continue to expand as a result of increasing use of genetic testing tools. It's possible that ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anticancer Potential of Ginger: Mechanistic and Pharmaceutical Aspects
Current Pharmaceutical Design Voltage-Gated Ion Channels, New Targets in Anti-Cancer Research
Recent Patents on Anti-Cancer Drug Discovery Cancer Chemoprevention by Dietary Phytochemicals: Promises and Pitfalls
Current Pharmaceutical Biotechnology Anticancer Activity of the Ascidian Polyclinum Indicum against Cervical Cancer Cells (HeLa) Mediated through Apoptosis Induction
Medicinal Chemistry Sentinel Node in Endometrial Cancer: Rationale and Early Experience
Current Women`s Health Reviews Natural and Synthetic Retinoids: Structural Bases and Biological Effects of Potential Clinical Relevance for the Prevention and Treatment of Infection-Driven Tumors
Anti-Infective Agents in Medicinal Chemistry The Metabolic Syndrome and HIV Infection
Current Pharmaceutical Design Activity of Saponins from Medicago species Against HeLa and MCF-7 Cell Lines and their Capacity to Potentiate Cisplatin Effect
Anti-Cancer Agents in Medicinal Chemistry Polysaccharide Colloids as Smart Vehicles in Cancer Therapy
Current Pharmaceutical Design P-Selectin Glycoprotein Ligand-1 as a Potential Target for Humoral Immunotherapy of Multiple Myeloma (Supplementry Material)
Current Cancer Drug Targets Valproic Acid As Anti-Cancer Drug
Current Pharmaceutical Design Organoselenium Compounds in Cancer Chemoprevention
Mini-Reviews in Medicinal Chemistry Dual EGFR and COX-2 Inhibition as a Novel Approach to Targeting Head and Neck Squamous Cell Carcinoma
Current Cancer Drug Targets Midkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System
Current Pharmaceutical Design Recent Advances of Small Molecule Focal Adhesion Kinase (FAK) Inhibitors as Promising Anticancer Therapeutics
Current Medicinal Chemistry Targeting IAPs as An Approach to Anti-Cancer Therapy
Current Topics in Medicinal Chemistry Challenges in the Correct Assessment of a Case of Aggressive Thyroid Carcinoma with Synchronous Breast Cancer: A Case Report and Review of the Literature of Essential Role of Radiopharmaceuticals
Current Radiopharmaceuticals Use of Anticancer Platinum Compounds in Combination Therapies and Challenges in Drug Delivery
Current Medicinal Chemistry Characterization and Inhibition of the Recently Discovered Carbonic Anhydrase Isoforms CA XIII, XIV and XV
Current Topics in Medicinal Chemistry Nitric Oxide Synthase and Cyclooxygenase Pathways: A Complex Interplay in Cellular Signaling
Current Medicinal Chemistry